Danish Construction Stock News

CPSE:MAERSK B
CPSE:MAERSK BShipping

Maersk Targets Defence Readiness With New UK Supply Chain Alliance

A.P. Møller - Mærsk has formed a new UK defence supply chain alliance with Amentum, GXO Logistics and Accenture. The partnership focuses on defence readiness and supply chain resilience for mission critical government operations. The move extends Maersk's integrated logistics offering into higher security, technology driven contracts in the defence sector. A.P. Møller - Mærsk (CPSE:MAERSK B) is adding a new leg to its business with this defence focused alliance, alongside its core global...
CPSE:KBHL
CPSE:KBHLInfrastructure

Assessing Københavns Lufthavne (CPSE:KBHL) Valuation After Stronger 2025 Sales And Profitability

Earnings event puts Københavns Lufthavne (CPSE:KBHL) in focus Københavns Lufthavne (CPSE:KBHL) just released full year 2025 results, reporting higher sales, revenue, and net income than the prior year. This has put the airport operator’s profitability and recent share performance under closer investor scrutiny. See our latest analysis for Københavns Lufthavne. The earnings release comes after a mixed year in the market, with the share price at DKK6,440 and recent gains such as a 1 day share...
CPSE:TRMD A
CPSE:TRMD AOil and Gas

Is TORM (CPSE:TRMD A) Pricing Reflect Long Term Value After Recent Share Pullback

If you are wondering whether TORM's current share price lines up with its underlying worth, you are not alone and this article is built to help you frame that question clearly. The stock last closed at DKK 158.70, after a 14.0% decline over the past week, a 0.6% decline over the last month, but with returns of 26.8% year to date and 45.0% over the past year. These moves have put TORM on the radar for investors who track shipping and tanker companies, and they raise the question of what is...
CPSE:NOVO B
CPSE:NOVO BPharmaceuticals

Is Novo Nordisk (CPSE:NOVO B) Pricing Reflect Recent 52% Slide And DCF Implied Value

If you are wondering whether Novo Nordisk's current share price really reflects its underlying worth, you are not alone. This article is here to walk you through that question step by step. After a strong long term story, the stock is now sitting at DKK 247.05 following a 0.3% decline over the last 7 days, a 19.4% decline over 30 days, a 25.2% decline year to date and a 52.1% decline over the past year, with a 22.2% return over 5 years and a 46.8% return over 3 years. Recent headlines around...
CPSE:GN
CPSE:GNConsumer Durables

Is GN Store Nord (CPSE:GN) Pricing Offer An Opportunity After Multi Year Share Price Slide

If you are wondering whether GN Store Nord's current share price reflects its true worth, you are not alone. This article is built to help you make sense of what the market is pricing in. GN Store Nord shares last closed at DKK 87.08, with returns of 6.2% decline over 7 days, 11.8% decline over 30 days, 20.8% decline year to date, 26.3% decline over 1 year, 39.0% decline over 3 years and 81.8% decline over 5 years. These moves may have shifted how investors think about both risk and...
CPSE:MAERSK B
CPSE:MAERSK BShipping

Is It Too Late To Reassess Maersk (CPSE:MAERSK B) After Its Strong 1-Year Rally?

Wondering if A.P. Møller - Mærsk is priced for its future or its past? This article walks you through what the current share price might be telling you about value. The stock closed at DKK 16,230, with returns of 6.6% over 30 days, 10.5% year to date and 46.1% over 1 year, so recent moves may have changed how you think about both upside and risk. Recent news has focused on Maersk's position in global container shipping and investor interest in how trade flows, freight demand and supply chain...
CPSE:STG
CPSE:STGTobacco

Assessing Scandinavian Tobacco Group (CPSE:STG) Valuation After Weaker 2025 Results And Reduced Dividend

Scandinavian Tobacco Group (CPSE:STG) has drawn fresh attention after reporting full year 2025 results with lower sales and net income, issuing 2026 guidance, and proposing a reduced DKK 4.50 dividend per share. See our latest analysis for Scandinavian Tobacco Group. The latest earnings release and reduced dividend appear to have weighed on sentiment, with a 30 day share price return showing a decline of 32.61% and a year to date share price return showing a decline of 29.47%, while the 1...
CPSE:VWS
CPSE:VWSElectrical

Is It Too Late To Consider Vestas (CPSE:VWS) After A 54% One-Year Rally?

If you are wondering whether Vestas Wind Systems is still priced attractively after a strong run, this article walks through how its current share price stacks up against different valuation checks. The stock trades at DKK159.70 after a 54.1% return over the past year, even though the 7 day, 30 day and year to date returns of 0.2% decline, 2.1% decline and 10.6% decline show that the ride has not been smooth. Recent coverage has focused on Vestas as a key player in global wind power build...
CPSE:COLO B
CPSE:COLO BMedical Equipment

Is There Now An Opportunity In Coloplast (CPSE:COLO B) After Sharp Share Price Slide

Investors may be wondering if Coloplast at around kr439.80 is starting to look interesting again, or if the current price still feels rich compared to its fundamentals. The share price has recorded a 4.7% decline over the last 7 days, a 10.6% decline over 30 days, an 18.0% decline year to date and a 37.1% decline over 1 year, while the 3 year and 5 year returns sit at declines of 41.9% and 45.6% respectively. These moves come as investors reassess the company against peers in the healthcare...
CPSE:BAVA
CPSE:BAVABiotechs

Bavarian Nordic Q4 Loss Tests Confidence In Strong Trailing Earnings Narrative

Bavarian Nordic (CPSE:BAVA) has wrapped up FY 2025 with Q4 revenue of DKK 1.5b and a basic EPS loss of DKK 4.13, capping a year in which trailing twelve month revenue came in at DKK 6.2b and basic EPS at DKK 17.6. Over the past few quarters, the company has seen revenue move from DKK 1.3b in Q1 2025 to DKK 1.8b in Q3 2025 before landing at DKK 1.5b in Q4, while quarterly basic EPS ranged from DKK 2.7 in Q1 and DKK 13.7 in Q3 to a loss in Q4. With trailing net profit margin at 22% compared to...
CPSE:GN
CPSE:GNConsumer Durables

GN Store Nord AGM Puts Cash Retention And Buyback Flexibility In Focus

GN Store Nord's latest Annual General Meeting approved the Annual Report and confirmed no dividend distribution for the period. Shareholders authorized the company to buy back treasury shares, subject to defined limits. The meeting also introduced new employee elected board members, replacing previous representatives. For GN Store Nord (CPSE:GN), these decisions come after a tough period for the share price. It is at DKK89.0 and has seen a 24.2% decline over the past year and an 81.2%...
CPSE:DANSKE
CPSE:DANSKEBanks

Assessing Danske Bank (CPSE:DANSKE) Valuation After Recent Share Price Pullback And Multi Year Gains

Why Danske Bank (CPSE:DANSKE) is drawing fresh attention Recent share price moves in Danske Bank (CPSE:DANSKE), including a decline over the past month along with a gain in the past 3 months, are prompting investors to reassess the bank’s current valuation and fundamentals. See our latest analysis for Danske Bank. The recent 1 month share price return of a 5.72% decline and 7 day softness sit against a year to date share price return of 1.16%. At the same time, the 1 year total shareholder...
CPSE:ALK B
CPSE:ALK BPharmaceuticals

A Look At ALK‑Abelló (CPSE:ALK B) Valuation After New EURneffy Preference Data At AAAAI 2026

ALK-Abelló (CPSE:ALK B) shares are in focus after the company reported new EURneffy user data at the AAAAI 2026 meeting, with 88% of trial participants preferring the needle free nasal adrenaline treatment to auto injectors. See our latest analysis for ALK-Abelló. The AAAAI data arrive after a softer patch for the shares, with a 1 day share price return of a 2.01% decline and a 7 day share price return of a 4.04% decline, even though the 1 year total shareholder return is 55.41% and the 3...
CPSE:NSIS B
CPSE:NSIS BChemicals

Novozymes (CPSE:NSIS B) Valuation Check After Recent Share Price Weakness

How Novozymes Shares Have Been Performing Novozymes (CPSE:NSIS B) has been under pressure recently, with the stock showing a 2.3% decline over the past day and deeper pullbacks over the past week, month, and past 3 months. Over the past year, Novozymes has delivered a total return of 9.6%. The year to date move reflects a 10.5% decline. Looking at longer periods, the 3 year total return stands at 11.9%, and the 5 year total return shows a 4.0% decline. See our latest analysis for...
CPSE:MAERSK B
CPSE:MAERSK BShipping

Does Maersk’s Middle East Service Suspension Reshape The Bull Case For A.P. Møller - Mærsk (CPSE:MAERSK B)?

A.P. Møller - Mærsk recently suspended key container services linking the Middle East with Europe and Asia, along with Gulf shuttle operations, and altered its ME1 rotation to bypass Jebel Ali as it responds to heightened security risks in the region. This shift reroutes cargo away from a major Middle Eastern hub, potentially reshaping how global shippers manage transit times, capacity, and supply chain resilience across these trade lanes. We’ll now examine how this temporary suspension of...
CPSE:ZEAL
CPSE:ZEALBiotechs

Zealand Pharma Weighs Petrelintide Progress Against Sharp Share Price Reset

Zealand Pharma reported positive Phase 2 topline results for petrelintide, its obesity drug candidate, with clinically meaningful weight loss and strong tolerability. The trial met its primary weight reduction endpoint and showed a favorable safety profile, according to the company. The news has arrived as investors reassess Zealand Pharma’s position in the obesity drug space and its collaboration with Roche. For holders of CPSE:ZEAL, the latest petrelintide data lands after a sharp reset...
CPSE:CARL B
CPSE:CARL BBeverage

Carlsberg India IPO Talks Put Spotlight On Growth And Shareholder Value

Carlsberg has confirmed it is considering an IPO of its India business. The company publicly acknowledged ongoing speculation around the India listing plans. The potential IPO would give investors a direct way to gain exposure to Carlsberg’s India operations. For investors watching CPSE:CARL B, the confirmation around a possible India IPO comes at a time when the shares trade at DKK969.2. The stock is up 13.6% over the past 30 days and 17.4% year to date, with a 12.3% return over 5 years...
CPSE:PAAL B
CPSE:PAAL BConstruction

Per Aarsleff Holding (CPSE:PAAL B) Is Down 6.2% After Earnings Beat And LiquiForce Partnership News

Per Aarsleff Holding A/S reported first-quarter 2025/26 results with sales rising to DKK 6,180 million and net income reaching DKK 187 million, modestly above the prior year. Separately, PURIS announced that PAA will become a part owner in a new LiquiForce partnership, extending Per Aarsleff’s technical footprint in Canadian infrastructure rehabilitation through shared LED-light curing and lateral renewal solutions. We’ll now examine how Per Aarsleff’s higher quarterly earnings and...
CPSE:TRMD A
CPSE:TRMD AOil and Gas

TORM (CPSE:TRMD A) Is Up 14.7% After Strong 2025 Results and 2026 TCE Guidance Update

TORM plc recently reported full-year 2025 results showing sales of US$1.34 billion and net income of US$285.3 million, alongside new 2026 TCE earnings guidance of US$850 million to US$1.25 billion. The board also approved a Q4 2025 interim dividend of US$0.70 per share, highlighting management’s willingness to return substantial cash to shareholders even as earnings moderated year over year. With this combination of firm 2026 TCE guidance and a sizeable Q4 dividend, we’ll now examine how the...
CPSE:ISS
CPSE:ISSCommercial Services

ISS Ownership Shift As Société Générale Trims Stake Below 5%

Société Générale has cut its shareholding in ISS A/S (CPSE:ISS) to below 5%, triggering a regulatory disclosure of a change in major shareholder status. The move marks a shift in ISS’s ownership structure that investors may watch for potential implications for governance and market sentiment. ISS, listed as CPSE:ISS, is a global facility services provider. Changes in its major shareholders tend to catch the eye of investors who follow long contract cycles and customer retention trends. The...
CPSE:ALK B
CPSE:ALK BPharmaceuticals

How ALK-Abelló’s 2025 Results, 2026 Outlook and R&D Shift Will Impact ALK-Abelló (CPSE:ALK B) Investors

ALK-Abelló A/S recently reported full-year 2025 results showing sales of DKK 6,312 million and net income of DKK 1,197 million, confirmed an 11–15% local-currency revenue growth outlook for 2026, announced an annual dividend of DKK 1.60 per share, and disclosed that EVP of R&D Henriette Mersebach will step down in February 2026 while supporting the transition. The combination of stronger earnings, growth guidance under the Allergy+ strategy, and a planned change in R&D leadership highlights...
CPSE:VWS
CPSE:VWSElectrical

How Vestas’ Vanguard West Offshore Win Will Impact Vestas Wind Systems (CPSE:VWS) Investors

On 20 February 2026, RWE announced a firm order with Vestas for 92 V236-15.0 MW turbines for the 1,380 MW Vanguard West offshore wind project in the UK, with Vestas supplying, delivering, commissioning, and servicing the turbines under a comprehensive multi-year agreement. This large UK offshore order highlights how Vestas’ V236 platform and service capabilities are being applied at utility scale across a major European project. We’ll now examine how securing this large Vanguard West...
CPSE:NOVO B
CPSE:NOVO BPharmaceuticals

Is Novo Nordisk (CPSE:NOVO B) Recasting Its Obesity Strategy After CagriSema Trails Zepbound?

In February 2026, Novo Nordisk reported phase 3 REDEFINE 4 data showing its CagriSema obesity injection delivered less weight loss than Eli Lilly’s Zepbound, while also outlining future high‑dose trials and ongoing REDEFINE and REIMAGINE programs across obesity and type 2 diabetes. At the same time, Novo Nordisk moved to defend its obesity and diabetes franchise with deeper Wegovy price cuts from 2027, an expanded Wegovy 7.2 mg dose in the EU, and new partnerships and pipeline assets,...
CPSE:DEMANT
CPSE:DEMANTMedical Equipment

Assessing Demant’s (CPSE:DEMANT) Valuation After US VA Gains And Expanded Cost Cuts

Why Demant (CPSE:DEMANT) Is Back in Focus for Investors Demant (CPSE:DEMANT) is drawing fresh attention after gaining market share in the US Veterans Affairs hearing aid channel, while at the same time expanding cost saving layoffs at its Danish operations. See our latest analysis for Demant. The recent gain in US Veterans Affairs market share and the expanded cost-saving program comes after a mixed price pattern, with an 8.07% 7-day share price return, a 30-day share price return of 11.11%,...